Intent to Sole Source Good Manufacturing Practices (GMP) Influenza A Primer Kits

The Centers for Disease Control and Prevention (CDC) intends to award a sole source contract to Biosearch Technologies Inc. for the manufacture of Good Manufacturing Practices (GMP) Influenza A Primer Kits. The purpose of this acquisition is to meet the current requirements for specifically designed oligonucleotide reagents of GMP quality level. The contractor will manufacture oligonucleotide primers using their validated process. • The NAICS code for this procurement is 325413, In-Vitro Diagnostic Substance Manufacturing. • The Influenza Division of the CDC monitors and investigates influenza viruses. • The division has created a method of amplifying all eight gene segments of Influenza A viruses in a one-step multi-segment reverse transcription polymerase chain reaction (M-RTPCR) reaction. • Firms that believe they can meet this requirement are encouraged to identify themselves and give written notice by providing a capability statement.